News and Trends 22 Jul 2020 Inhaled Treatment Reduces Severe Covid-19 Risk by 79% …In the trial, the lead candidate of UK-based biotech Synairgen drove down by 79% the risk of severe disease symptoms such as requiring mechanical ventilation in hospitalized Covid-19 patients. Among… July 22, 2020 - 3 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
More News! 4 Nov 2022 Optibrium and Lhasa Limited study published on predictive modelling for enzymes …Unexpected metabolism can cause the failure of many late-stage drug candidates, or even the withdrawal of approved drugs. It is therefore essential to predict metabolism for potential drug candidates. Current… November 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Expert Advice 14 Jun 2024 Biotech valuation multiples: how to value a biotech company? …share of it. Investing in early-stage companies is risky; during the years it takes to get a drug through research, clinical trials, and regulatory review, the drug candidate can fail… June 14, 2024 - 12 minutesmins - By Carlos de Rojas Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2017 Merck expands its Oncology Pipeline beyond Checkpoint Inhibitors …Pharmaceuticals for the worldwide rights to four oncology programs. Merck has paid €220M ($230M) upfront for two clinical-stage DNA damage and repair candidates and two additional preclinical programs, of which… January 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 May 2020 Italian Pharma Getting Back to Normal With Two Biotech Acquisitions …recent acquisition was of French immuno-oncology company ElsaLys Biotech by Mediolanum Farmaceutici, a pharmaceutical group based in Milan. The French biotech has several candidate drugs in development. The most advanced… May 11, 2020 - 4 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2017 MorphoSys’ First Lanthipeptide Completes Phase I Successfully …with its lanthipeptide candidate MOR107, which is being developed as a therapy for diabetic nephropathy. Lanthio Pharma, a Dutch subsidiary of the big German antibody biotech MorphoSys, has initiated its… May 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 11 Apr 2023 Is a vaccine for Parkinson’s disease possible? …an unmet need for a more preventative treatment option. With this in mind, alongside developing small molecule and monoclonal antibody treatments, researchers and biotechs are also exploring the possibility of… April 11, 2023 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2022 Providence Therapeutics’ mRNA rabies vaccine hits milestone …rabies vaccine candidate produced higher levels of serum neutralizing antibodies than those of mice dosed with the comparator vaccine. Providence’s candidate also induced a significantly higher degree of T-cell-mediated immune… December 16, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 Poseida Therapeutics and Roche to focus on therapies for hematologic malignancies …a research program to create and develop next-generation features and improvements for allogeneic CAR-T therapies, from which they would jointly develop additional allogeneic CAR-T product candidates directed to existing and… August 3, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2017 Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic …team might find some competition from GSK, which is running Phase II with an anti-GM-CSF antibody from the German Morphosys to treat inflammatory hand osteoarthritis. Down the line, the German… May 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Apr 2020 Update: BioNTech and Pfizer’s mRNA Vaccine for Covid-19 Tested in Humans …Pfizer for 50% of the costs during the commercialization stage. The two partners plan to begin phase I testing of multiple mRNA vaccine candidates for Covid-19 this month. If the… April 29, 2020 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 19 Jan 2024 Re-coding the brain: Is CRISPR capable of curing neurodegenerative diseases? …CRISPR/dCas9-editing strategy to lower the levels of APOE-e4. The lead candidate from this platform was found to reduce APOE-e4 levels in human induced pluripotent stem cell-derived miniature brains from an… January 19, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email